If the remaining study results are equally as noteworthy, Gilead should have a strong case for a historically quick approval for Remdesivir in the United States, and perhaps in several international territories as well. The Food and Drug Administration has already signaled that it is willing to green-light a viable COVID-19 treatment in record time.

The big deal from an investing standpoint is that an approval should land Gilead a multibillion-dollar payday. While Remdesivir's price point probably won't be as rich as Gilead's other antiviral medications, there should be more than enough demand to push this drug into blockbuster territory (sales greater than $1 billion per year) within a few short months. 

The full results from this late-stage trial should be released any day now. As such, biotech investors will definitely want to keep a close eye on this rapidly developing story. 

Companies fighting the coronavirus pandemic have seen mixed success, but good news in their efforts has generally resulted in big moves higher for their stocks. That was the case today for Gilead Sciences (NASDAQ: GILD) and Moderna (NASDAQ: MRNA), and some see further gains ahead if these biotechs can make good on their promises to produce solutions in treating COVID-19.